WHO calls for closer monitoring of commercial interestsBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7328.8c (Published 05 January 2002) Cite this as: BMJ 2002;324:8
- Rohit Sharma
Commercial interests are posing such an increasing threat to the integrity of clinical trials necessary for developing new drugs that new regulations are needed to safeguard them from corruption, according to Dr Jonathan Quick, director of essential drugs and medical policy at the World Health Organization.
In an editorial in the current Bulletin of …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial